Study Reveals How Listeria Breaches the Placenta

Article

A gut bacterium called Listeria (Listeria monocytogenes), which is often found in soft cheese, is known to present a risk to pregnant women. Listeria uses distinct tactics to breach the intestine and the placenta, using a protein called phosphoinositide-3 kinase (PI3-K), according to a study published in the Journal of Experimental Medicine.

Listeria has two proteins that help it cross mucosal tissue barriers. Both proteins, called internalins A and B, attach to tissue receptors and are needed for Listeria to invade the placenta, but protein A alone can propel Listeria across the intestine. What underlies these differences has remained unknown.

Tissue invasion by Listeria also requires the enzyme PI3-K. This enzyme is turned on by both of the Listeria’s internalin proteins, but only the B protein has a built-in activation mechanism. Lecuit and colleagues at the Pasteur Institute in France have been able to visualize the activation of PI3-K, finding that this enzyme is very important for Listeria invasiveness via internalins. They uncover that PI3-K is perpetually turned on in intestinal cells, using only internalin A and rendering internalin B dispensable. The placenta, by contrast, has little to no inherent PI3-K activity, which is why passage of the bug through the placenta requires both A and B internalins.

These findings open up exciting new opportunities to examine whether other microbes-in addition to those posing a pregnancy risk-are capable of crossing host barriers using PI3-K activation, and whether this mechanism of bug invasion also occurs in other mucosal tissues and organs.

Reference: Gessain G., et al. 2015. J. Exp. Med. doi:10.1084/jem.20141406

Source: The Rockefeller University Press 

Recent Videos
 Darren Goff, executive director of hospitality services at Cameron Memorial Community Hospital in Angola, Indiana.
Isis Lamphier, MPH, MHA, CIC; Tori Whitacre Martonicz, MA; and Heather Stoltzfus, MPH, RN, CIC, at APIC Conference and Expo 2024 (Photo courtesy of Tori Whitacre Martonicz)
Lindsay K. Weir, MPH, CIC, Lead Infection Preventionist/Infection Preventionist III
•	Rebecca (Bartles) Crapanzano-Sigafoos, DrPH, MPH, CIC, FAPIC (corresponding author), executive director of APIC’s Center for Research, Practice, and Innovation, and lead author of the study.
Infection Control Today's Infection Intel: Staying Ahead With Company Updates and Product Innovations.
COVID-19 presentations at IDWeek in Las Angeles, California by Invivyd.   (Adobe Stock 333039083 by Production Perig)
Long COVID and Other Post-Viral Syndromes
Meet Jenny Hayes, MSN, RN, CIC, CAIP, CASSPT.
Infection Control Today Editorial Advisory Board: Fibi Attia, MD, MPH, CIC.
Andrea Thomas, PhD, DVM, MSc, BSc, director of epidemiology at BlueDot
Related Content